JAK2 and neoplasm: In another instance, the inhibition (both pharmacologically and genetically) of Janus kinase 2 (JAK2), a signal transducer and an activator of the transcription 3 (STAT3) pathway, in PTEN-loss-induced cellular senescent (PICS) tumours in mice was found to enhance chemotherapy, by decreasing the level of immunosuppressive cytokines while maintaining the level of immunostimulatory cytokines, which allowed for the induction of a strong anti-tumour immune response [225].